Other serious, ongoing, non-malignant disease or infection that would compromise protocol objectives Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor Medical or psychiatric illnesses that, in the investigator's opinion, may impact the safety of the subject or the objectives of the study. Serious non-malignant disease that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor. Subject requires any medical intervention(s) or has any other condition(s) that, in the Investigator’s opinion, will 1) make the administration of PROSTVAC or ipilimumab hazardous, 2) obscure the interpretation of adverse events (AEs), 3) compromise adherence with study requirements, or 4) otherwise compromise the study’s objectives Any medical intervention, any other condition, or any other circumstance which, in the opinion of the investigator, could compromise adherence with study requirements or otherwise compromise the study’s objectives Serious non-malignant disease such as active infection or other condition which in the opinion of the investigator would compromise other protocol objectives Any medical intervention or other condition which, in the opinion of the principal investigator, could compromise adherence with study requirements or otherwise compromise the study’s objectives Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the trial, and/or compromise the objectives of the trial Serious, ongoing, non-malignant disease or infection, which in the opinion of the investigator and/or the sponsor would compromise other protocol objectives; participants with active opportunistic infections are ineligible Serious nonmalignant disease that could compromise protocol objectives in the opinion of the investigator and/or the sponsor Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator Other serious, ongoing, non-malignant disease or infection that would in the opinion of the site investigator compromise other protocol objectives hepatic, renal neurological or metabolic conditions - which in the opinion of the investigator would compromise the protocol objectives. Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance. Any other condition or circumstance that could interfere with adherence to the study’s procedures or requirements, or otherwise compromise the study’s objectives such as history of, or any evidence of active, non-infectious pneumonitis Any other current or previous malignancy within the past three years that, in the opinion of the Principal Investigator, will interfere with study-specific objectives. Any serious medical or psychiatric illness, including drug or alcohol abuse that could, in the investigator's opinion, potentially jeopardize the safety of the participant or interfere with the objectives of the study. Significant acute or chronic medical, neurologic, or psychiatric illness in the subject that, in the judgment of the principal investigator, could compromise subject safety, limit the subject’s ability to complete the study, and/or compromise the objectives of the study Any concomitant condition that in the opinion of the Investigator could compromise the objectives of this study and the patient's compliance. Other condition(s) that in the opinion of the investigator might compromise the objectives of the study Serious nonmalignant disease which, in the opinion of the investigator would compromise protocol objectives Patients or their representative who are unable to understand the conditions and objectives of the study Current or prior disease or treatment that could compromise protocol objectives in the opinion of the Investigator and/or the Sponsor Other condition(s) that in the opinion of the investigator might compromise the objectives of the study or increase patient risk Any medical intervention or other condition which, in the opinion of the principal investigator could compromise adherence with study requirements or otherwise compromise the study's objectives Serious, ongoing, non-malignant disease or infection, which in the opinion of the investigator and/or the sponsor would compromise other protocol objectives; participants with active opportunistic infections are ineligible Any condition that compromises compliance with the objectives and procedures of this protocol Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor. Any medical intervention or other condition which, in the opinion of the principal investigator could compromise adherence with study requirements or otherwise compromise the study’s objectives Any concomitant condition that in the opinion of the investigator could compromise the objectives of this study and the patient's compliance. Serious non-malignant disease (e.g., active uncontrolled bacterial, viral, or fungal infections) or other medical conditions (including psychiatric) which, in the opinion of the Principal Investigator (PI) would compromise other protocol objectives Serious nonmalignant or malignant disease or psychiatric illness, which, in the opinion of the investigator would compromise protocol objectives or interfere with participation Have active infection that would interfere with the study objectives or influence study compliance Any medical intervention, condition or any other circumstance which in the opinion of the investigator or the sponsor's medical monitor, could compromise adherence to study procedures or study objectives. Serious nonmalignant disease (e.g., hydronephrosis, liver failure, heart failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor. Active alcohol abuse or other illness or circumstance that carries a likelihood of inability to comply with study treatment and follow-up or otherwise compromise the study’s objectives Serious nonmalignant disease (e.g., hydronephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor. Patients may not have any concomitant condition that could compromise the objectives of this study and the patients' compliance and ability to tolerate this therapy and complete at least 2 cycles of therapy, including, but not limited to the following: Serious nonmalignant disease (e.g., congestive heart failure, hydronephrosis); active uncontrolled bacterial, viral, or fungal infections; or other conditions which would compromise protocol objectives in the opinion of the investigator Has a medical or psychiatric condition or other circumstances which would significantly decrease the chances of obtaining reliable data, achieving study objectives, or completing the study and/or post-dose follow-up examinations. Medical exclusions include: patients with a history of myocardial infarction or ischemic heart disease within the past six months; patients with history of epilepsy, brain damage, or symptomatic brain metastases; skin conditions such as open sores that would prevent proper application of the electrodes; or other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study Other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study Significant acute or chronic medical, neurologic, or psychiatric illness in the subject that, in the judgment of the principal investigator, could compromise subject safety, limit the subject’s ability to complete the study, and/or compromise the objectives of the study Other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study Other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study Other medical or other condition(s) that in the opinion of the investigators might compromise the objectives of the study Any medical condition or other circumstances that in the opinion of the investigators compromise obtaining reliable data or achieving the study objectives Subjects with any medical condition or other circumstance that, in the opinion of the investigator, compromise obtaining reliable data, achieving study objectives, or completion. Cohort A Only: Have a medical condition or other circumstances that, in the opinion of the investigator would significantly decrease the chances of obtaining reliable data, achieving the study objectives, or completing the trial. Inclusion Criteria:\n\n 1. Patients with selected solid malignancies (NSCLC, SCLC, SqCCHN, melanoma, merkel cell\n tumor, renal, bladder, hepatocellular, triple negative breast, or gastroesophageal\n cancer) or Hodgkin's lymphoma\n\n 2. At least 1 measurable lesion documented on CT/MRI (RECIST criteria 1.1)\n\n 3. Eastern Cooperative Oncology Group (ECOG) performance status ? 2 (Appendix B: ECOG\n Scoring)\n\n 4. Age ? 18 years\n\n 5. Ability to understand the purposes and risks of the trial and has signed a\n IRB-approved informed consent form\n\n 6. Willingness and ability to comply with all protocol required procedures\n\n 7. For men and women of child-bearing potential, use of effective contraceptive methods\n during the study\n\n Exclusion Criteria:\n\n Patients meeting any of the following criteria will not be eligible for study entry:\n\n 1. Known infection with human immunodeficiency virus (HIV)\n\n 2. Serious nonmalignant disease or conditions that in the opinion of the investigator\n and/or ImaginAb could compromise protocol objectives\n\n 3. Patients who have had splenectomy.\n\n 4. Patients who have any splenic disorders that in the opinion of the investigator and/or\n ImaginAb could compromise protocol objectives.\n\n 5. Patients who are currently receiving any other investigational agent\n\n 6. Pregnant women or nursing mothers\n\n 7. Hepatic laboratory values:\n\n 1. Bilirubin > 1.5 x ULN (institutional upper limits of normal)\n\n 2. Albumin < 2 g/dL\n\n 3. Other local safety laboratory test results (clinical chemistry and hematology)\n are determined to be exclusionary by the Investigator.\n\n 8. Known sensitivity to glutamic acid or glutamate. Have any medical condition or other circumstances that, in the opinion of the investigator, would significantly decrease obtaining reliable data, achieving study objectives or completing the study Has any other medical condition or other circumstances that would significantly decrease the chances of obtaining reliable data or of achieving the study objectives such as:\r\n* Mental illness\r\n* Drug abuse Any medical condition that in the opinion of the investigators could potentially jeopardize the safety of the patient, limit the patient’s ability to complete the study, and/or compromise the objectives of the study Have a medical condition or other circumstances which, in the opinion of the investigator would significantly decrease the chances of obtaining reliable data, achieving the study objectives, or completing the study. Have a medical condition or other circumstances that, in the opinion of the investigator would significantly decrease the chances of obtaining reliable data, achieving the study objectives, or completing the trial. Significant acute or chronic medical, neurologic, or psychiatric illness in the subject that, in the judgment of the investigator, could compromise subject safety, limit the subject’s ability to complete the study, and/or compromise the objectives of the study